Home LiteratureArticle Details
PMID: 27855702 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Genome biology ·Vol. 17 ·No. 1 ·2016-00-17 ·Pages 231

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA

Abstract

Tumor-infiltrating immune cells have been linked to prognosis and response to immunotherapy; however, the levels of distinct immune cell subsets and the signals that draw them into a tumor, such as the expression of antigen presenting machinery genes, remain poorly characterized. Here, we employ a gene expression-based computational method to profile the infiltration levels of 24 immune cell populations in 19 cancer types. We compare cancer types using an immune infiltration score and a T cell infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the highest for both scores. Using immune infiltration profiles as well as transcriptomic and proteomic datasets, we characterize three groups of ccRCC tumors: T cell enriched, heterogeneously infiltrated, and non-infiltrated. We observe that the immunogenicity of ccRCC tumors cannot be explained by mutation load or neo-antigen load, but is highly correlated with MHC class I antigen presenting machinery expression (APM). We explore the prognostic value of distinct T cell subsets and show in two cohorts that Th17 cells and CD8+ T/Treg ratio are associated with improved survival, whereas Th2 cells and Tregs are associated with negative outcomes. Investigation of the association of immune infiltration patterns with the subclonal architecture of tumors shows that both APM and T cell levels are negatively associated with subclone number. Our analysis sheds light on the immune infiltration patterns of 19 human cancers and unravels mRNA signatures with prognostic utility and immunotherapeutic biomarker potential in ccRCC.

Keywords
Cancer immunotherapy Checkpoint blockade Clear cell renal cell carcinoma (ccRCC) Computational deconvolution Tumor immune microenvironment
MeSH Terms
CD8-Positive T-Lymphocytes/immunology Carcinoma, Renal Cell/genetics,immunology,therapy Computer Simulation Gene Expression Regulation, Neoplastic Humans Immunotherapy Lymphocytes, Tumor-Infiltrating/immunology Neoplasm Proteins/biosynthesis Nucleotide Motifs/genetics Prognosis Proteomics RNA, Messenger/biosynthesis,genetics Tumor Microenvironment/genetics,immunology
Chemicals
Neoplasm Proteins RNA, Messenger
Authors & Affiliations
29 authors, click to expand affiliations / ORCID
Şenbabaoğlu Yasin
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shenbaba@gmail.com. | Present address: Swim Across America/Ludwig Collaborative Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shenbaba@gmail.com.
Gejman Ron S
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Weill Cornell Medical College, New York, NY, USA.
Winer Andrew G
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Liu Ming
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Van Allen Eliezer M
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
de Velasco Guillermo
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Miao Diana
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ostrovnaya Irina
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Drill Esther
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luna Augustin
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weinhold Nils
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lee William
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Manley Brandon J
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Khalil Danny N
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kaffenberger Samuel D
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chen Yingbei
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Danilova Ludmila
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. | Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
Voss Martin H
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Coleman Jonathan A
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Russo Paul
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Reuter Victor E
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chan Timothy A
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Weill Cornell Medical College, New York, NY, USA.
Cheng Emily H
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Scheinberg David A
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Weill Cornell Medical College, New York, NY, USA.
Li Ming O
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Choueiri Toni K
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hsieh James J
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sander Chris
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hakimi A Ari
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hakimia@mskcc.org. | Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hakimia@mskcc.org.
References (84)
84 references, click to expand
  1. Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma.
    Urol Int. 2002;69(1):51-6 PMID: 12119440
  2. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
    J Exp Med. 2002 Sep 2;196(5):619-28 PMID: 12208877
  3. Random forest: a classification and regression tool for compound classification and QSAR modeling.
    J Chem Inf Comput Sci. 2003 Nov-Dec;43(6):1947-58 PMID: 14632445
  4. Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence.
    J Clin Pathol. 1992 Dec;45(12):1084-8 PMID: 1479035
  5. The three Es of cancer immunoediting.
    Annu Rev Immunol. 2004;22:329-60 PMID: 15032581
  6. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer.
    Cancer Res. 2004 Aug 15;64(16):5535-8 PMID: 15313886
  7. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
    Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S PMID: 15448028
  8. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets.
    J Immunol. 2005 Dec 15;175(12):7837-47 PMID: 16339519
  9. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
    Cancer Cell. 2006 Apr;9(4):287-300 PMID: 16616334
  10. Adjusting batch effects in microarray expression data using empirical Bayes methods.
    Biostatistics. 2007 Jan;8(1):118-27 PMID: 16632515
  11. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
    Cancer. 2006 Jul 1;107(1):46-53 PMID: 16708355
  12. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells.
    J Leukoc Biol. 2006 Dec;80(6):1529-41 PMID: 16966385
  13. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  14. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.
    J Virol. 2007 Apr;81(7):3477-86 PMID: 17251300
  15. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.
    Cancer Res. 2007 Mar 1;67(5):1883-6 PMID: 17332313
  16. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
    Clin Cancer Res. 2007 Mar 15;13(6):1757-61 PMID: 17363529
  17. NetMHCpan, a method for MHC class I binding prediction beyond humans.
    Immunogenetics. 2009 Jan;61(1):1-13 PMID: 19002680
  18. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
    Nat Protoc. 2009;4(1):44-57 PMID: 19131956
  19. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks.
    Bioinformatics. 2009 Apr 15;25(8):1091-3 PMID: 19237447
  20. TopHat: discovering splice junctions with RNA-Seq.
    Bioinformatics. 2009 May 1;25(9):1105-11 PMID: 19289445
  21. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.
    Blood. 2009 Aug 6;114(6):1141-9 PMID: 19470694
  22. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt.
    Nat Protoc. 2009;4(8):1184-91 PMID: 19617889
  23. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
    Nature. 2009 Nov 5;462(7269):108-12 PMID: 19847166
  24. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    J Clin Oncol. 2009 Dec 10;27(35):5944-51 PMID: 19858404
  25. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.
    Genome Biol. 2009;10(11):R130 PMID: 19919682
  26. VHL and HIF signalling in renal cell carcinogenesis.
    J Pathol. 2010 Jun;221(2):125-38 PMID: 20225241
  27. T(H)17 cells in tumour immunity and immunotherapy.
    Nat Rev Immunol. 2010 Apr;10(4):248-56 PMID: 20336152
  28. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.
    Genes Cancer. 2010 Feb 1;1(2):152-163 PMID: 20871783
  29. Differential expression analysis for sequence count data.
    Genome Biol. 2010;11(10):R106 PMID: 20979621
  30. Towards a systems understanding of MHC class I and MHC class II antigen presentation.
    Nat Rev Immunol. 2011 Nov 11;11(12):823-36 PMID: 22076556
  31. Expression of tumour-specific antigens underlies cancer immunoediting.
    Nature. 2012 Feb 08;482(7385):405-9 PMID: 22318517
  32. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
    Nature. 2012 Feb 08;482(7385):400-4 PMID: 22318521
  33. RNA-SeQC: RNA-seq metrics for quality control and process optimization.
    Bioinformatics. 2012 Jun 1;28(11):1530-2 PMID: 22539670
  34. Absolute quantification of somatic DNA alterations in human cancer.
    Nat Biotechnol. 2012 May;30(5):413-21 PMID: 22544022
  35. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway.
    Angiogenesis. 2012 Sep;15(3):457-68 PMID: 22562362
  36. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  37. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility.
    PLoS One. 2012;7(7):e41361 PMID: 22848472
  38. Emerging immunotherapies for renal cell carcinoma.
    Ann Oncol. 2012 Sep;23 Suppl 8:viii35-40 PMID: 22918926
  39. RazerS 3: faster, fully sensitive read mapping.
    Bioinformatics. 2012 Oct 15;28(20):2592-9 PMID: 22923295
  40. STAR: ultrafast universal RNA-seq aligner.
    Bioinformatics. 2013 Jan 1;29(1):15-21 PMID: 23104886
  41. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα.
    Cell Stem Cell. 2012 Dec 7;11(6):812-24 PMID: 23168163
  42. GSVA: gene set variation analysis for microarray and RNA-seq data.
    BMC Bioinformatics. 2013 Jan 16;14:7 PMID: 23323831
  43. DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data.
    Bioinformatics. 2013 Apr 15;29(8):1083-5 PMID: 23428642
  44. Macrophage regulation of tumor responses to anticancer therapies.
    Cancer Cell. 2013 Mar 18;23(3):277-86 PMID: 23518347
  45. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Sci Signal. 2013 Apr 02;6(269):pl1 PMID: 23550210
  46. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  47. Spontaneous regression of renal cell carcinoma.
    Contemp Oncol (Pozn). 2013;17(2):123-7 PMID: 23788977
  48. Comprehensive molecular characterization of clear cell renal cell carcinoma.
    Nature. 2013 Jul 4;499(7456):43-9 PMID: 23792563
  49. Integrated molecular analysis of clear-cell renal cell carcinoma.
    Nat Genet. 2013 Aug;45(8):860-7 PMID: 23797736
  50. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.
    Cancer Cell. 2013 Aug 12;24(2):229-41 PMID: 23871637
  51. Oncology meets immunology: the cancer-immunity cycle.
    Immunity. 2013 Jul 25;39(1):1-10 PMID: 23890059
  52. SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis.
    J Cell Biol. 2013 Sep 16;202(6):937-50 PMID: 24019535
  53. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
    J Clin Oncol. 2013 Nov 10;31(32):e439-42 PMID: 24043743
  54. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
    Circ Res. 2013 Nov 8;113(11):1231-41 PMID: 24047927
  55. Innate and adaptive immune cells in the tumor microenvironment.
    Nat Immunol. 2013 Oct;14(10):1014-22 PMID: 24048123
  56. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser.
    Sci Rep. 2013 Oct 02;3:2652 PMID: 24084870
  57. Inferring tumour purity and stromal and immune cell admixture from expression data.
    Nat Commun. 2013;4:2612 PMID: 24113773
  58. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
    J Pathol. 2013 Dec;231(4):424-32 PMID: 24122851
  59. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
    Immunity. 2013 Oct 17;39(4):782-95 PMID: 24138885
  60. Systematic evaluation of spliced alignment programs for RNA-seq data.
    Nat Methods. 2013 Dec;10(12):1185-91 PMID: 24185836
  61. FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.
    Oncotarget. 2014 Jan 15;5(1):264-76 PMID: 24406338
  62. Regulatory T cells in cancer immunotherapy.
    Curr Opin Immunol. 2014 Apr;27:1-7 PMID: 24413387
  63. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
    Nat Genet. 2014 Mar;46(3):225-233 PMID: 24487277
  64. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies.
    Biomed Res Int. 2014;2014:730246 PMID: 24900982
  65. Tumor-associated macrophages: from mechanisms to therapy.
    Immunity. 2014 Jul 17;41(1):49-61 PMID: 25035953
  66. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.
    PLoS Comput Biol. 2014 Aug 07;10(8):e1003665 PMID: 25102416
  67. OptiType: precision HLA typing from next-generation sequencing data.
    Bioinformatics. 2014 Dec 1;30(23):3310-6 PMID: 25143287
  68. HTSeq--a Python framework to work with high-throughput sequencing data.
    Bioinformatics. 2015 Jan 15;31(2):166-9 PMID: 25260700
  69. Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma.
    Mol Med Rep. 2015 Feb;11(2):947-53 PMID: 25352158
  70. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    N Engl J Med. 2014 Dec 4;371(23):2189-2199 PMID: 25409260
  71. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
    Nature. 2014 Nov 27;515(7528):563-7 PMID: 25428504
  72. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  73. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
    Nature. 2014 Nov 27;515(7528):572-6 PMID: 25428506
  74. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Nature. 2014 Nov 27;515(7528):577-81 PMID: 25428507
  75. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Clin Cancer Res. 2015 Mar 15;21(6):1329-39 PMID: 25583177
  76. Molecular and genetic properties of tumors associated with local immune cytolytic activity.
    Cell. 2015 Jan 15;160(1-2):48-61 PMID: 25594174
  77. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Science. 2015 Apr 3;348(6230):124-8 PMID: 25765070
  78. Robust enumeration of cell subsets from tissue expression profiles.
    Nat Methods. 2015 May;12(5):453-7 PMID: 25822800
  79. Profiling tissue-resident T cell repertoires by RNA sequencing.
    Genome Med. 2015 Nov 30;7:125 PMID: 26620832
  80. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
    Science. 2016 Mar 25;351(6280):1463-9 PMID: 26940869
  81. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
    Immunity. 2016 Mar 15;44(3):698-711 PMID: 26982367
  82. Monoclonal antibody 123C3, identifying small cell carcinoma phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues.
    Int J Cancer Suppl. 1988;2:34-40 PMID: 2832332
  83. Commentary on: "An integrated metabolic atlas of clear cell renal cell carcinoma." Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ.: Cancer Cell. 2016 Jan 11;29(1):104-16.
    Urol Oncol. 2017 Sep;35(9):579-580 PMID: 28789930
  84. Angiogenesis in cancer, vascular, rheumatoid and other disease.
    Nat Med. 1995 Jan;1(1):27-31 PMID: 7584949
Article Info
Journal
Genome biology
Abbr.
Genome Biol
ISSN
1474-760X
Published
2016-00-17
Epub
2016-00-17
Pages
231
Language
English
Region
England
NLM ID
100960660
PMCID
PMC5114739
Subset
IM
Grants
NCI NIH HHS · R01 CA055349 · United States
NHGRI NIH HHS · U41 HG006623 · United States
NCI NIH HHS · F30 CA200327 · United States
NCI NIH HHS · P01 CA023766 · United States
NIGMS NIH HHS · P41 GM103504 · United States
NCI NIH HHS · P30 CA008748 · United States
NCI NIH HHS · U24 CA143840 · United States
NCI NIH HHS · T32 CA082088 · United States
NIGMS NIH HHS · T32 GM007739 · United States
Corrections
ErratumIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com